Viscosupplementation Market by Product (Five Injection, Single Injection, Three Injection), Source (Animal, Non-animal), Application, End-use - Global Forecast 2024-2030

[184 Pages Report] The Viscosupplementation Market size was estimated at USD 2.83 billion in 2023 and expected to reach USD 3.01 billion in 2024, at a CAGR 6.19% to reach USD 4.32 billion by 2030.

Viscosupplementation is a medical procedure involving the injection of hyaluronic acid into a joint, such as the knee, to relieve pain caused by conditions such as osteoarthritis. As a non-surgical treatment option, viscosupplementation aims to improve joint function, reduce pain, and possibly delay joint replacement surgery. Increasing incidences of joint disorders and sport-related injuries, a growing elderly population that is more susceptible to such ailments, and the rising preference for minimally invasive procedures significantly contribute to market growth. However, the existence of alternative treatment options, including steroid injections and non-pharmacologic therapies, may impede market growth. Nevertheless, technological advancements in formulating and delivering hyaluronic acid and healthcare infrastructure improvements are expected to create potential opportunities for developing the viscosupplementation market.

The five-injection regimen is a viscosupplementation treatment consisting of five hyaluronic acid (HA) injections. This course of therapy is typically administered once per week over five consecutive weeks. Primarily used for the management of knee osteoarthritis, this treatment aims to restore the lubricating and cushioning properties of the synovial fluid in the joint. The Single-Injection Regimen offers an alternative approach to viscosupplementation with the convenience of a one-time injection. This product is formulated with a high concentration of hyaluronic acid and often includes cross-linking agents that enhance the durability and longevity of the treatment within the joint. The Three-Injection Regimen is a widely adopted viscosupplementation treatment that involves a series of three hyaluronic acid injections. These are typically administered one week apart and are designed to supplement the viscous properties of synovial fluid in the joint space. The primary goal of this treatment is to relieve pain and enhance mobility in patients with osteoarthritis. The three-injection regimen strikes a balance between the more extensive five-injection course and the single-injection alternative, offering a middle ground in terms of treatment commitment and duration of symptom relief.

Animal-based sources have been the primary means of obtaining hyaluronic acid for viscosupplementation. Animal-based sources utilize tissues from rooster combs, which are rich in hyaluronic acid or are extracted from other avian tissues. Non-animal-based hyaluronic acid is produced through bacterial fermentation processes. Genetically modified strains of bacteria, such as Streptococcus zooepidemicus, are used to biosynthesize high-purity HA. Non-animal HA is considered safe and effective, eliminating the risks associated with avian proteins that can cause hypersensitivity reactions. Additionally, non-animal-based HA has been gaining popularity due to ethical considerations and consistency in production.

Hyaluronic acid is directly injected into the affected joint in the viscosupplementation treatment for hand osteoarthritis. This treatment is used when traditional non-surgical treatments such as pain medications and physical therapy have not provided adequate relief. The main benefit of viscosupplementation for hand osteoarthritis lies in its pain reduction and, hence, improvement in function and quality of life. Viscosupplementation is a proven therapeutic measure to alleviate pain and improve functionality in patients with hip osteoarthritis, particularly those not responding to conventional treatments. The procedure for the hip joint is more complex, often requiring ultrasound or X-ray guidance due to the hip's deep-seated nature. A key advantage of viscosupplementation in hip osteoarthritis is its superior safety profile compared to long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). Knee osteoarthritis is the most common application for viscosupplementation since the knee is a major weight-bearing joint and, therefore, is highly susceptible to wear and tear. The viscosupplementation procedure aims to restore the natural properties of the synovial fluid lost to knee osteoarthritis.

Hospitals represent a significant end-use sector for viscosupplementation, a therapeutic option for patients suffering from osteoarthritis, particularly in the knee joint. As comprehensive medical facilities with a multidisciplinary approach, hospitals are pivotal in providing this minimally invasive procedure. Viscosupplementation involves the intra-articular injection of hyaluronic acid to lubricate the joint, alleviate pain, and improve mobility. Orthopedic clinics and Ambulatory Surgical Centers (ASCs) are specialized end-use settings where viscosupplementation is frequently administered. These centers are predominantly focused on musculoskeletal health, making them highly adept at providing targeted therapies like viscosupplementation. The convenience, efficiency, and typically lower costs associated with ASCs make them an attractive option for patients seeking outpatient care.

The market is evolving in the Americas owing to the growing incidence of osteoarthritis, high healthcare expenditure, increasing preference for minimally invasive procedures, and widespread availability of several FDA-approved HA products. Advanced healthcare systems, increased awareness about osteoarthritis treatment options, and supportive regulatory frameworks are encouraging the growth of the viscosupplementation market in Europe. The Middle East and Africa viscosupplementation market is growing with improving availability and affordability of treatment and the prevalence of competitive treatment modalities for osteoarthritis. The Asia Pacific region represents significant demand for viscosupplementation due to high osteoarthritis prevalence, expanding healthcare infrastructure, and increasing accessibility to advanced osteoarthritis treatments. Besides, ongoing research to improve the efficacy of viscosupplementation therapy is anticipated to propel the demand for the viscosupplementation market globally.

The FPNV Positioning Matrix is pivotal in evaluating the Viscosupplementation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Viscosupplementation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• KiOmed Pharma and Arsylab Announce Strategic Partnership for the Promotion and Distribution in France of KioMedinevsone, a New Class of Treatment for Refractory Knee Osteoarthritis

  Kiomed Pharma and ARSYLAB have entered a strategic partnership to promote and distribute KIOMEDINEVS.ONE, a breakthrough treatment class for individuals suffering from refractory knee osteoarthritis in France. This innovative therapy represents a new direction in viscosupplementation, offering a promising option for patients. [Published On: 2023-09-17]

• Anika’s Cingal Successfully Achieves Primary Endpoint in Third Phase III Study

  Anika Therapeutics completed a Phase 3 clinical trial for its innovative product, CINGAL. CINGAL is specifically formulated to provide effective treatment for the symptoms of osteoarthritis through intra-articular viscosupplementation. The primary endpoint of the study clearly demonstrated that a single intra-articular injection of CINGAL outperformed placebo in improving patient symptom scores at the 24-week mark. [Published On: 2022-11-01]

The report delves into recent significant developments in the Viscosupplementation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Anika Therapeutics, Inc., Avanos Medical, Inc., Bausch Health Companies Inc., Bioventus LLC, Contipro A.S., DePuy Synthes by Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Ferring B.V., Fidia Farmaceutici S.p.A., Gentex Pharma, LLC, LG Chem Ltd., Lifecore Biomedical, LLC, Quimfa S.A., Regen Lab SA, Sanofi S.A., Seikagaku Corporation, Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zimmer Biomet.

This research report categorizes the Viscosupplementation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Five Injection
  • Single Injection
  • Three Injection
• Source
  • Animal
  • Non-animal
• Application
  • Hand Osteoarthritis
  • Hip Osteoarthritis
  • Knee Osteoarthritis
• End-use
  • Hospitals
  • Orthopedic Clinics/Ambulatory Surgical Centers (ASCs)

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

1. What is the market size and forecast of the Viscosupplementation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Viscosupplementation Market?
3. What are the technology trends and regulatory frameworks in the Viscosupplementation Market?
4. What is the market share of the leading vendors in the Viscosupplementation Market?
5. Which modes and strategic moves are suitable for entering the Viscosupplementation Market?